Simvastatin intervention mitigates hypercholesterolemia-induced alveolar bone resorption in rats

Area of Science:

• Periodontology
• Pharmacology
• Bone Biology

Background:

• Hyperlipidemia is linked to increased alveolar bone resorption and poorer periodontal health.
• Simvastatin's effects on hypercholesterolemia-induced alveolar bone loss and its underlying mechanisms remain unclear.

Purpose of the Study:

• To investigate the therapeutic efficacy of simvastatin in hypercholesterolemia-induced alveolar bone resorption.
• To elucidate the potential mechanisms by which simvastatin modulates this condition.

Main Methods:

• A human study correlated hyperlipidemia with periodontal parameters.
• A rat model of hypercholesterolemia was established, with some rats receiving simvastatin treatment.
• Alveolar bone resorption, NF-κB, OPG, RANKL, LC3, and p62 levels were analyzed.

Main Results:

• Hyperlipidemia patients exhibited significantly worse periodontal health.
• Rats fed a high-cholesterol diet showed increased alveolar bone resorption, NF-κB, and RANKL/OPG ratios.
• Simvastatin treatment reduced bone loss and RANKL, while increasing LC3/p62 ratios.

Conclusions:

• Hyperlipidemia is associated with alveolar bone resorption.
• Simvastatin alleviates hypercholesterolemia-related alveolar bone loss by down-regulating NF-κB expression.